Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan

Hirotaka Katada, Naoichiro Yukawa, Hisashi Urushihara, Shiro Tanaka, Tsuneyo Mimori, Koji Kawakami

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

This drug utilization study aimed to investigate prescription patterns and trends for anti-rheumatic drug use in Japanese patients with rheumatoid arthritis (RA), clarifying if patients with RA in Japan are being treated according to EULAR recommendations and ACR guidelines. We used a large-scale claims database consisting of the medical claims of employee health insurance recipients, which included approximately one million insured people. The claims data for incident 5,126 patients with diagnosis codes of RA between January 1, 2005 and October 31, 2011 were analyzed. The number of patients who received disease modifying anti-rheumatic drugs (DMARDs) including biologics as initial therapy was 629 (12.3 %), while the others received non-DMARD therapy only. During the study period, use of methotrexate (MTX) and biologics as first-line drugs increased from 1.9 to 8.0 % and from 0 to 1.6 %, respectively (p <0.001 for both), while that of non-steroidal anti-inflammatory drugs (NSAIDs) decreased (p = 0.004). Time from first RA diagnosis to the start of treatment with DMARDs decreased significantly from 2005 to 2010. These findings suggest that many early RA patients in Japan do not yet receive aggressive treatment, albeit that this prescribing practice has gradually changed to better comply with clinical recommendations. The current, obsolete Japanese RA guidelines require urgent updating to reflect the most recent knowledge and care with effective treatment modalities.

Original languageEnglish
Pages (from-to)949-956
Number of pages8
JournalClinical Rheumatology
Volume34
Issue number5
DOIs
Publication statusPublished - 2015 May 1
Externally publishedYes

Fingerprint

Antirheumatic Agents
Prescriptions
Rheumatoid Arthritis
Japan
Databases
Biological Products
Guidelines
Drug Utilization
Occupational Health
Therapeutics
Health Insurance
Methotrexate
Pharmaceutical Preparations
Anti-Inflammatory Agents
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. / Katada, Hirotaka; Yukawa, Naoichiro; Urushihara, Hisashi; Tanaka, Shiro; Mimori, Tsuneyo; Kawakami, Koji.

In: Clinical Rheumatology, Vol. 34, No. 5, 01.05.2015, p. 949-956.

Research output: Contribution to journalArticle

Katada, Hirotaka ; Yukawa, Naoichiro ; Urushihara, Hisashi ; Tanaka, Shiro ; Mimori, Tsuneyo ; Kawakami, Koji. / Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. In: Clinical Rheumatology. 2015 ; Vol. 34, No. 5. pp. 949-956.
@article{f7e8620e389b47859e5aa8137d5f6a2f,
title = "Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan",
abstract = "This drug utilization study aimed to investigate prescription patterns and trends for anti-rheumatic drug use in Japanese patients with rheumatoid arthritis (RA), clarifying if patients with RA in Japan are being treated according to EULAR recommendations and ACR guidelines. We used a large-scale claims database consisting of the medical claims of employee health insurance recipients, which included approximately one million insured people. The claims data for incident 5,126 patients with diagnosis codes of RA between January 1, 2005 and October 31, 2011 were analyzed. The number of patients who received disease modifying anti-rheumatic drugs (DMARDs) including biologics as initial therapy was 629 (12.3 {\%}), while the others received non-DMARD therapy only. During the study period, use of methotrexate (MTX) and biologics as first-line drugs increased from 1.9 to 8.0 {\%} and from 0 to 1.6 {\%}, respectively (p <0.001 for both), while that of non-steroidal anti-inflammatory drugs (NSAIDs) decreased (p = 0.004). Time from first RA diagnosis to the start of treatment with DMARDs decreased significantly from 2005 to 2010. These findings suggest that many early RA patients in Japan do not yet receive aggressive treatment, albeit that this prescribing practice has gradually changed to better comply with clinical recommendations. The current, obsolete Japanese RA guidelines require urgent updating to reflect the most recent knowledge and care with effective treatment modalities.",
author = "Hirotaka Katada and Naoichiro Yukawa and Hisashi Urushihara and Shiro Tanaka and Tsuneyo Mimori and Koji Kawakami",
year = "2015",
month = "5",
day = "1",
doi = "10.1007/s10067-013-2482-1",
language = "English",
volume = "34",
pages = "949--956",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "5",

}

TY - JOUR

T1 - Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan

AU - Katada, Hirotaka

AU - Yukawa, Naoichiro

AU - Urushihara, Hisashi

AU - Tanaka, Shiro

AU - Mimori, Tsuneyo

AU - Kawakami, Koji

PY - 2015/5/1

Y1 - 2015/5/1

N2 - This drug utilization study aimed to investigate prescription patterns and trends for anti-rheumatic drug use in Japanese patients with rheumatoid arthritis (RA), clarifying if patients with RA in Japan are being treated according to EULAR recommendations and ACR guidelines. We used a large-scale claims database consisting of the medical claims of employee health insurance recipients, which included approximately one million insured people. The claims data for incident 5,126 patients with diagnosis codes of RA between January 1, 2005 and October 31, 2011 were analyzed. The number of patients who received disease modifying anti-rheumatic drugs (DMARDs) including biologics as initial therapy was 629 (12.3 %), while the others received non-DMARD therapy only. During the study period, use of methotrexate (MTX) and biologics as first-line drugs increased from 1.9 to 8.0 % and from 0 to 1.6 %, respectively (p <0.001 for both), while that of non-steroidal anti-inflammatory drugs (NSAIDs) decreased (p = 0.004). Time from first RA diagnosis to the start of treatment with DMARDs decreased significantly from 2005 to 2010. These findings suggest that many early RA patients in Japan do not yet receive aggressive treatment, albeit that this prescribing practice has gradually changed to better comply with clinical recommendations. The current, obsolete Japanese RA guidelines require urgent updating to reflect the most recent knowledge and care with effective treatment modalities.

AB - This drug utilization study aimed to investigate prescription patterns and trends for anti-rheumatic drug use in Japanese patients with rheumatoid arthritis (RA), clarifying if patients with RA in Japan are being treated according to EULAR recommendations and ACR guidelines. We used a large-scale claims database consisting of the medical claims of employee health insurance recipients, which included approximately one million insured people. The claims data for incident 5,126 patients with diagnosis codes of RA between January 1, 2005 and October 31, 2011 were analyzed. The number of patients who received disease modifying anti-rheumatic drugs (DMARDs) including biologics as initial therapy was 629 (12.3 %), while the others received non-DMARD therapy only. During the study period, use of methotrexate (MTX) and biologics as first-line drugs increased from 1.9 to 8.0 % and from 0 to 1.6 %, respectively (p <0.001 for both), while that of non-steroidal anti-inflammatory drugs (NSAIDs) decreased (p = 0.004). Time from first RA diagnosis to the start of treatment with DMARDs decreased significantly from 2005 to 2010. These findings suggest that many early RA patients in Japan do not yet receive aggressive treatment, albeit that this prescribing practice has gradually changed to better comply with clinical recommendations. The current, obsolete Japanese RA guidelines require urgent updating to reflect the most recent knowledge and care with effective treatment modalities.

UR - http://www.scopus.com/inward/record.url?scp=84954205594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954205594&partnerID=8YFLogxK

U2 - 10.1007/s10067-013-2482-1

DO - 10.1007/s10067-013-2482-1

M3 - Article

C2 - 24420724

AN - SCOPUS:84891751276

VL - 34

SP - 949

EP - 956

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 5

ER -